LEXICON PHARMACEUTICALS, INC.

Analyst Reco. Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
1.74 ^USD	+2.35%		+10.13%	+13.73%

May. 02	Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02	Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target	Apr. 30	MT
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	Mar. 25	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	23-10-10	DJ
Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating	23-05-31	MT
Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target	23-03-07	MT
Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage	22-08-12	MT
Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target	22-08-12	MT
Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating	22-07-01	MT
LEXICON PHARMACEUTICALS : Wedbush Suspended Coverage on Lexicon Pharmaceuticals	21-10-11	MT
LEXICON PHARMACEUTICALS : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating	21-08-30	MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept	21-05-11	MT
LEXICON PHARMACEUTICALS : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7	21-01-29	MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2	21-01-29	MT
LEXICON PHARMACEUTICALS : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10	20-12-08	MT
LEXICON PHARMACEUTICALS : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold	20-11-18	MT
LEXICON PHARMACEUTICALS : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating	20-11-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer